新型甲基受体1/2激动剂限制高血压引起的心血管损伤
Jaideep Singh1,2, Kristy L Jackson1,2, Haoyun Fang2,3
1Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052, Australia.
Cardiovascular research
|June 16, 2024
概括
化合物17b (Cmpd17b) 是一种甲基受体 (FPR) 激动剂,通过减少炎症和改善心血管功能,有效治疗高血压引起的器官损伤. 这项研究强调了Cmpd17bb.
科学领域:
- 心血管研究研究心血管研究
- 炎症和免疫学 炎症和免疫学
- 蛋白质组学是指蛋白质组学.
背景情况:
- 甲基受体 (FPR) 是炎症的关键调节器,是高血压引起的末端器官损伤的主要原因.
- 以前的研究表明,化合物17b (Cmpd17b) 是一种偏向的FPR激动剂,可以提供对急性炎症攻击的心脏保护.
研究的目的:
- 研究Cmpd17b对高血压引起的末端器官损伤中持续性炎症的治疗潜力.
- 探索小鼠和人类高血压蛋白质之间的相似之处.
主要方法:
- ангиотензин II (Ang II) 输液用于诱导小鼠的高血压.
- 进行Cmpd17b治疗以评估其对心脏和血管功能,纤维化和化的影响.
- 用质谱测量进行了心脏和大动脉组织的蛋白质学分析,以分析蛋白质表达变化.
主要成果:
- 在小鼠中,Cmpd17b减轻了高血压,改善了心脏和血管功能,减少了纤维化和化.
- Cmpd17b正常化Ang II诱导的线粒体复合体2呼吸.
- 蛋白质组分析确定了与高血压相关的蛋白质集群,并揭示了Cmpd17b减轻这些失调的能力,约110种蛋白质在人类中显示出类似的失调.
结论:
- 该FPR激动剂Cmpd17b在限制高血压诱导的末端器官损伤方面显示出显著的治疗潜力.
- 这些发现支持开发基于FPR的治疗方法,用于管理系统性高血压的并发症.
- 该研究提供了蛋白质学证据,将FPR活性与高血压中的心血管健康联系起来.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
420
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
420
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
706
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
706
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
153
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
153
01:23Antihypertensive Drugs: Vasodilators
503
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
503
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
166
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
166
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K